Results

1–10 of 54 results for age-related macular degeneration (AMD)

Novel Handheld Device for Remote Monitoring of Non-neovascular Age-Related Macular Degeneration andClinical Validation of Usability and Comfort
Yannis M Paulus, MD
Annual Meeting Talks
2025
Intended vs Actual Intervals Between Intravitreal Anti-VEGF Injections and Assessment of Treatment Delays
Christina Y Weng, MD, MBA, FASRS
Annual Meeting Talks
2023
Faricimab Rapidly Improves Fluid Parameters in Patients With nAMD
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2023
Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration With Intravitreal ANX007: Results of the ARCHER Study
Jeffrey S. Heier, MD
Annual Meeting Talks
2023
An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD
Marco A. Zarbin, MD, PhD
Annual Meeting Talks
2023
Phase III Randomized Clinical Trial Comparing SB15 With Reference Aflibercept in Neovascular Age-Related Macular Degeneration 56-Week Results
Min Sagong, MD
Annual Meeting Talks
2023
Subgroup Analyses From the Phase 3 PULSAR Trial of Aflibercept 8 mg in Patients With Treatment-Naïve Neovascular Age-Related Macular Degeneration
Keyvan Koushan, MD, FRCSC
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg in Patients With Polypoidal Choroidal Vasculopathy Phase 3 PULSAR Trial Subgroup Analysis
David T.W. Wong, MD, FRCS(C), FASRS
Annual Meeting Talks
2023
Baseline Characteristics of Patients Maintaining q12 and q16 Dosing With Aflibercept 8 mg vs Patients With Shortened Treatment Intervals Phase 3 PULSAR Post Hoc Analysis
David R. Chow, MD, FRCS(C)
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg Injection in Patients With Neovascular Age-Related Macular Degeneration: 48-week Results From the Phase 3 PULSAR Trial
Jignesh I Patel, MD FRCOphth
Annual Meeting Talks
2023